Cisplatin

Study finds cisplatin less effective than standard treatment for patients with anal cancer

HOUSTON - When administered before chemoradiation, the common anti-cancer drug cisplatin neither improved disease-free survival nor reduced the number of colostomies needed when compared to the standard treatment for patients with anal canal cancer, according to a study published in the April 23 i...

Researchers Have Identified Subgroup Sensitive to the Drug Cisplatin

Researchers have identified a subgroup of hard-to-treat breast cancers that may be sensitive to the drug cisplatin, rarely used in the treatment of breast tumors. They also have discovered// the molecular basis of this sensitivity, which may help identify patients most likely to benefit from cispla...

Nanoparticle-delivered 'Suicide' Genes Slowed Ovarian Tumor Growth

...weeks and suppressed tumor growth more effectively, and with minimal non-specific cytotoxicity, than in mice treated with clinically relevant doses of cisplatin and paclitaxel. Edward Sausville, M.D., Ph.D., an associate editor of Cancer Research and associate director for clinical research at the Greeneba...

Lilly to Unveil More Than 30 Studies at Premier Lung Cancer Meeting

...g Phase II Study of Pemetrexed plus Carboplatin or cisplatin with Concurrent Radiation Therapy Followed by Peme... ALIMTA is approved by the FDA in combination with cisplatin (another chemotherapy drug) for the initial treatm...n) GEMZAR is indicated in combination with cisplatin (another type of chemotherapy) for the first-line ...

Lilly Receives Fourth FDA Approval for ALIMTA(R) (pemetrexed for injection)

...cutive approvals: it was the first agent to be approved in combination with cisplatin as a treatment for patients with malignant pleural mesothelioma, whose dise...ormation for ALIMTA ALIMTA is approved by the FDA in combination with cisplatin (another chemotherapy drug) for the initial treatment of advanced nonsquamo...

MDOUTLOOK(R) Quick Polls Report on Clinical Integration of Key Oncology Developments Following ASCO 2009

...ill be the new standard-of-care for relapsed, platinum-sensitive ovarian cancer For advanced cervical cancer, the combination of gemcitabine + cisplatin will be the new standard-of-care concerning choice of chemotherapy. Maintenance therapy in Non-Small Cell Lung Cancer: ...

Nicotine Receptors Could Be Lung Cancer Treatment Target

...therapy drug group; and the α-CbT group. Mice that were categorized as non-obese/severe combined immunodeficient (NOD/SCID) and treated with cisplatin (the standard chemotherapy agent) were found to have a 16 percent longer median survival time than untreated mice. NOD/SCID mice treated with α-C...

Immune-Based Lymphoma Treatment Shows Promise

...e also repairs DNA purposely damaged by chemotherapy. Not surprisingly, then, patients with either low levels of MSH2 or none at all respond better to cisplatin treatment than patients with higher levels. "The findings duplicate those of a prior study that showed similar results with a different DNA repair ...

Avastin Shows No Benefit Against Early Stage Colon Cancer

...l cancer -- radiation therapy plus 5-FU and mitomycin-C chemotherapy -- remains the best bet for patients with this rare malignancy. Chemotherapy with cisplatin showed no superior benefit, according to researchers at the National Cancer Research Institute in Britain. The authors also concluded that maintenance...

ALIMTA(R) (pemetrexed for injection) Receives Positive Opinion From CHMP as Maintenance Therapy for Nonsquamous Non-Small Cell Lung Cancer

...or injection), Lilly Important Safety Information for ALIMTA (pemetrexed for injection) ALIMTA is approved by the FDA in combination with cisplatin (another chemotherapy drug) for the initial treatment of advanced nonsquamous non-small cell lung cancer (NSCLC), a specific type of NSCLC. ALIMTA is ...

Cisplatin in Medical Technology

Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer

Promising Preliminary Results on Radiation Sensitization from Phase II Trial May Serve as Additional Registration Direction for OPAXIO ORLANDO, Fla., June 3 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that, in a study released from Brown U...

Alfacell Provides Shareholder Update

...ed Onconase has a documented synergistic effect in cisplatin sensitive and resistant NSCLC. We are not surprise...y in mice bearing tumors of varying sensitivity to cisplatin and Carbo Platinum. In all of the animal models, the addition of Onconase to cisplatin significantly increased the tumor growth inhibitio...

Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients

...anced cervical cancer consists of the chemotherapy cisplatin and radiation (chemoradiation). This has been the...between both. Patients on arm A were treated with cisplatin (40 mg/m(2)) and gemcitabine (125 mg/m(2)) weekly ...of gemcitabine (1000 mg/m(2)) on days 1 and 8 plus cisplatin (50 mg/m(2)) on day 1. Patients on arm B were tre...

Induction Chemotherapy Followed by ChemoRadiotherapy Increased Time-to-Treatment Failure Compared to ChemoRadiotherapy Alone in Patients With Unresectable Locally Advanced Head & Neck Cancer

...who were randomly assigned to receive standard CRT (cisplatin and fractionated radiation) versus the same treatment preceded by IC, which consisted of cisplatin plus 5-fluorouracil (5-FU) with or without Taxotere(R) (docetaxel) Injection Concentrate. The study was designed to compare the results of those patie...

Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting

...phoma and Plasma Cell Disorders, May 30, 8:00 a.m.-12:00 p.m. Advanced Cancers Leal TB, et al. A phase I study of AT-101 in combination with cisplatin (P) and etoposide (E) in patients with advanced solid tumors and extensive-stage small cell lung cancer (ES-SCLC). Abstract #e13502; Publication only...

EntreMed Presents Initial Clinical Results for ENMD-2076

...nted results from a preclinical evaluation of ENMD-2076 in combination with cisplatin in a multi-drug resistant, triple-negative human breast carcinoma model. Tr... the combination is well tolerated when using a maximally tolerated dose of cisplatin and a range of ENMD-2076 doses. Studies demonstrate a substantial dose-dep...

A Milestone in Cancer Genetics: deCODE Discovers First Common Genetic Variants Affecting the Risk of Many Types of Cancer

...riant, a SNP called rs 401681, in its gene discovery work on basal cell carcinoma (BCC), a common form of skin cancer. The SNP is in the gene encoding cisplatin resistance related protein 9 (CLPTM1L). Because the region of chromosome 5p15 is of interest in cancer biology, the deCODE team then tested this SNP f...

PLC Systems Defers Pivotal Study of RenalGuard(TM) in the U.S.

...ean Union (EU) capitalizing on the automated fluid balancing capabilities of our system. Specifically, there are several medical applications, such as cisplatin chemotherapy, where inducing high urine flow rates is beneficial for patients and is a standard of care. High urine flow rates are also frequently see...

BioNumerik Pharmaceuticals Observes Evidence of a Survival Increase in Lung Cancer Patients Participating in Tavocept(TM) Clinical Trial

...etaxel (sold under the brand name Taxotere(R)) and cisplatin every two weeks. Approximately half of the patient...who received the chemotherapy drugs paclitaxel and cisplatin every three weeks. Half of the patients in the tri...nic groups. Since the U.S. Tavocept Trial involved cisplatin and the taxane drug docetaxel while the Japan Tavo...

Canopus BioPharma Strengthens its CB1400 Platform Technology for Mucositis and Oncology Treatments Through License Agreement With Wisconsin Alumni Research Foundation

... Canopus as an anti-mucositis preventative agent in patients receiving radio- and/or chemotherapy treatment. CB1400 alone and in combination with both cisplatin and cetuximab (Erbitux), has also been shown to inhibit tumor growth in two mice models of lung cancer, thus demonstrating the broad capabilities of t...

Cisplatin in Medical Dictionary

Concomitant

... concomitant boost) ... Taxanes Plus Radiation and Concomitant Boost Radiation With or Without Chemotherapy ... For concomitant chemotherapy, cisplatin was used in five trials and carboplatin in one trial. ... chemotherapy after concomitant chemotherapy. Pages: 1 ... Learn about the prescript...

Cisplatin in Biological News

Light activated anticancer drug targeted to DNA using cisplatin like sub-units

One of the most effective chemotherapy drugs against cancer is cisplatin because it attaches to cancer DNA and disrupts repair. However, it also kills healthy tissue. Many scientists are creating alternative drugs or cisplatin analogs in attempts to find treatments without side effects. One approac...

New cancer drug delivery system is effective and reversible

...ls had died, while less than 12 percent of breast cancer cells treated with cisplatin alone had died. "By labeling a liposome that contains cisplatin with a cancer cell-specific aptamer, we have shown delivery of the drugs to...

Nanoparticle-delivered 'suicide' genes slowed ovarian tumor growth

...weeks and suppressed tumor growth more effectively, and with minimal non-specific cytotoxicity, than in mice treated with clinically relevant doses of cisplatin and paclitaxel. Edward Sausville, M.D., Ph.D., an associate editor of Cancer Research and associate director for clinical research at the Greenebau...

Twin nanoparticle shown effective at targeting, killing breast cancer cells

...-2 tumor cell and unloads the cancer-fighting drug cisplatin directly into the infected cell. The result: Great...xide nanoparticle. On the other end, they attached cisplatin to the gold nanoparticle. Visually, the whole cont...ent bond to connect the gold nanoparticle with the cisplatin to ensure that the drug was not released into the ...

Team finds breast cancer gene linked to disease spread

...tal organs and bones. Importantly, these tumors were also found to be more resistant to a wide range of chemotherapeutic agents, including paclitaxel, cisplatin and adriamycin. When researchers genetically altered the cancer cells to reduce the expression of MTDH, these tumor cells become less able to metastas...

MIT nanotubes sniff out cancer agents in living cells

...rugs and other DNA-damaging agents inside living cells. The sensors, made of carbon nanotubes wrapped in DNA, can detect chemotherapy drugs such as cisplatin as well as environmental toxins and free radicals that damage DNA. "We've made a sensor that can be placed in living cells, healthy or malignant, a...

Dealing deadly cancers a knockout punch

...esults of the preclinical study showed that the combination of reovirus and cisplatin was significantly more effective than cisplatin or reovirus alone at killing melanoma cancer cells in a mouse model. The i...

Chemo combination improves survival in asbestos-related cancer

... In the study, patients receiving pemetrexed and cisplatin ?along with the vitamin supplements folic acid and...d nearly three months longer than patients getting cisplatin alone. Researchers led by John Green, M.D., ...ination. "Pemetrexed used in combination with cisplatin significantly increases the length of survival, wh...

Molecular signature may identify cisplatin-sensitive breast tumors

...help identify patients most likely to benefit from cisplatin treatment. The findings will be tested in a clini...estion and to investigate the mechanism underlying cisplatin sensitivity. The research team focused on th...ng with p73’s normal ability to induce cell death. cisplatin was found to break up the binding of p63 to p73 an...

Intravenous nanoparticle gene therapy shows activity in stage IV lung cancer

...bly to a seven-month median survival time for patients receiving second line therapy. All patients on the trial had been treated with front line cisplatin combination chemotherapy, which failed to halt their disease. The clinical trial continues. No maximum tolerated dose has been established, Lu says....

Cisplatin in Biological Technology

Oncolytics Biotech Inc. Collaborators to Present Preclinical Combination REOLYSIN(R) and Cisplatin Research at EORTC-NCI-AACR Annual Meeting

CALGARY, Oct. 22 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that a poster presentation authored by Prof. Hardev Pandha of The Royal Surrey Hospital, U.K., entitled "Synergistic Anti-Tumour Activity of Oncolytic Reovirus and Cisplatin in a B16.F10 ...

CB1400, Patented by Canopus BioPharma, Prevents Tumor Growth and Enhances the Anti-Tumor Effects of Cisplatin and Cetuximab (Erbitux).

LOS ANGELES, California, June 19 /PRNewswire-FirstCall/ -- Canopus BioPharma, Inc. (OTC: CBIA), has confirmed the efficacy of its oncology candidate, CB1400, as a tumor reducing agent and has also demonstrated the synergistic effect of this drug in combination with both cisplatin and cetuximab...

Celator(R) Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio of Irinotecan and Cisplatin to Improve Anti-tumor Activity

Promising pre-clinical results support advance to clinical study for third combination chemotherapy from Celator based on the company's proprietary CombiPlex(TM) technology platform. PRINCETON, N.J., Oct. 26 /PRNewswire/ -- Celator Pharmaceuticals today announced positive re...

Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting

... Gastric Cancer A Phase I Dose-Finding Study of Sorafenib in Combination with Capecitabine and cisplatin as a First-Line Treatment in Patients with Advanced Gastric Cancer. Chul Kim, M.D., Yoon-Koo Kang, M.D., Asan Medical Center, Seoul, Re...

Lilly Set to Unveil More Than 50 Studies at ASCO 2009

...aluating the Cost-Effectiveness of Pemetrexed plus cisplatin as First-line Therapy for Advanced Non-Small Cell ... study comparing concurrent gemcitabine (Gem) plus cisplatin (Cis) and radiation followed by adjuvant Gem plus ... 4:30 p.m. Gemcitabine with or without cisplatin in patients (pts) with advanced or metastatic bili...

Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data

...t a poster at the CTOS meeting entitled "Systemic Administration of REOLYSIN Inhibits Growth of Human Sarcoma Xenografts Alone and in Combination with cisplatin and Radiation." About Oncolytics Biotech Inc. Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses ...

Lilly to Acquire ImClone Systems in $6.5 Billion Transaction

...gle-arm trial with ERBITUX, radiation therapy, and cisplatin (100 mg/m2) in patients with locally advanced squa... ALIMTA is approved by the FDA in combination with cisplatin (another chemotherapy drug) for the initial treatm...r GEMZAR GEMZAR is indicated in combination with cisplatin (another type of chemotherapy) for the first-line ...

Oncolytics Biotech Inc. Collaborators to Present REOLYSIN(R) Clinical Trial

... deliver a poster presentation entitled "Systemic Administration of Reolysin Inhibits Growth of Human Sarcoma Xenografts Alone and in Combination with cisplatin and Radiation" at the CTOS meeting. Prof. Hardev Pandha and colleagues are scheduled to deliver a poster presentation at the EORTC-AACR-NCI Symposiu...

SuperGen Reports 2008 Second Quarter Financial Results

... anti-tumor activity in prostate and cisplatin-resistant ovarian carcinoma xenograft models. Additionally, S-110 restored sensitivity to cisplatin in the ovarian cancer model. Reduced toxicity was observed along with an increased half-life compared to decitabine. -- June 2008: The Compa...

Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting

...stract #2545, poster discussion, Sunday, June 1, 2008, 2 - 6 p.m., S Hall A1 -- A phase II study: Combination of sorafenib with docetaxel and cisplatin in the treatment of metastatic or advanced unresectable gastric and gastroesophageal junction (GEJ) adenocarcinoma (ECOG 5203) -- Weijing ...